Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT07382544
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Cancer
  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this clinical research study is to learn about the safety and effects of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss.

Key Dates

Start date
Feb 12, 2026
Status verified
Feb 2026
Primary completion
Jan 31, 2030
Completion
Jan 31, 2032

Study Design

Enrollment
36 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Part A Dose Escalation: Treatment with BMS-986504 + Olaparib
    Study treatment will be administered on an outpatient basis
  • Experimental: Part B Pharmacodynamic Expansion Cohort 1: Treatment with BMS-986504 at C1D1 + Olaparib at C1D15
    Study treatment will be administered on an outpatient basis
  • Experimental: Part B Pharmacodynamic Expansion Cohort 2: Treatment with Olaparib at C1D1 + BMS-986504 at C1D15
    Study treatment will be administered on an outpatient basis

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas M. D. Anderson Cancer CenterHoustonTexas77030
Jordi Rodon Ahnert, MD, PHD
[email protected]
713-792-5603
Jordi Rodon Ahnert, MD, PHD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
The University of Texas M. D. Anderson Cancer Center· Houston, TX

Related Studies